The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials

Journal of Statistical Planning and Inference

Volumn 138, Issue 2, 2008, Pages 432-449

  Molenberghs, Geert ^a   Burzykowski, Tomasz ^a   Alonso, Ariel ^a   Assam, Pryseley ^a   Tilahun, Abel ^a   Buyse, Marc ^a,b  

^a HASSELT UNIVERSITY   (Belgium)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

Hierarchical model; Likelihood reduction factor; Meta analysis; Random effects model; Surrogate endpoint; Surrogate threshold effect

Indexed keywords

EID: 35348845780     PISSN: 03783758     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jspi.2007.06.005     Document Type: Article

References (40)

1. Alonso A., and Molenberghs G. Surrogate marker evaluation from an information theoretic perspective. Biometrics 63 (2006) 180-186
2. Alonso A., Geys H., Molenberghs G., and Vangeneugden T. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements. Biometrical J. 45 (2003) 931-945
3. Alonso A., Molenberghs G., Burzykowski T., Renard D., Geys H., Shkedy Z., Tibaldi F., Abrahantes J., and Buyse M. Prentice's approach and the meta analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 60 (2004) 724-728
4. Alonso A., Molenberghs G., Geys H., and Buyse M. A unifying approach for surrogate marker validation based on Prentice's criteria. Statist. Med. 25 (2005) 205-211
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69 (2001) 89-95
6. Burzykowski T., and Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm. Statist. 5 (2006) 173-186
7. Burzykowski T., Molenberghs G., Buyse M., Renard D., and Geys H. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. Appl. Statist. 50 (2001) 405-422
8. Burzykowski T., Molenberghs G., and Buyse M. The validation of surrogate endpoints using data from randomized clinical trials: a case-study in advanced colorectal cancer. J. Roy. Statist. Soc. Ser. A 167 (2004) 103-124
9. Burzykowski T., Molenberghs G., and Buyse M. The Evaluation of Surrogate Endpoints (2005), Springer, New York
10. Buyse M., and Molenberghs G. The validation of surrogate endpoints in randomized experiments. Biometrics 54 (1998) 1014-1029
11. Buyse M., Molenberghs G., Burzykowski T., Renard D., and Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1 (2000) 49-67
12. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction. N. Engl. J. Med. 321 (1989) 406-412
13. Clayton D.G. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 65 (1978) 141-151
14. Cortiñas A.J., Molenberghs G., Burzykowski T., Shkedy Z., and Renard D. Choice of units of analysis and modeling strategies in multilevel hierarchical models. Comput. Statist. Data Anal. 47 (2004) 537-563
15. Cover T., and Tomas J. Elements of Information Theory (1991), Wiley, New York
16. Dale J.R. Global cross ratio models for bivariate, discrete, ordered responses. Biometrics 42 (1986) 909-917
17. Daniels M.J., and Hughes M.D. Meta-analysis for the evaluation of potential surrogate markers. Statist. Med. 16 (1997) 1515-1527
18. DeGruttola V., and Tu X.M. Modelling progression of CD-4 lymphocyte count and its relationship to survival time. Biometrics 50 (1994) 1003-1014
19. Ferentz A.E. Integrating pharmacogenomics into drug development. Pharmacogenomics 3 (2002) 453-467
20. Fleming T.R., and DeMets D.L. Surrogate endpoints in clinical trials: are we being misled?. Ann. Intern. Med. 125 (1996) 605-613
21. Freedman L.S., Graubard B.I., and Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statist. Med. 11 (1992) 167-178
22. Gail M.H., Pfeiffer R., and van Houwelingen H.C. On meta-analytic assessment of surrogate outcomes. Biostatistics 1 (2000) 231-246
23. Galecki A. General class of covariance structures for two or more repeated factors in longitudinal data analysis. Comm. Statist. Theory Methods 23 (1994) 3105-3119
24. Genest C., and McKay J. The joy of copulas: bivariate distributions with uniform marginals. Amer. Statist. 40 (1986) 280-283
25. Hougaard P. Survival models for heterogeneous populations derived from stable distributions. Biometrika 73 (1986) 387-396
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Fed. Regist. 63 179 (1998) 49583
27. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 13 (1987) 261-276
28. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatr. Res. 23 (1988) 99-110
29. Lagakos S.W., and Hoth D.F. Surrogate markers in AIDS: where are we? Where are we going?. Ann. Intern. Med. 116 (1992) 599-601
30. Lesko L.J., and Atkinson A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria validation strategies. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 347-366
31. Molenberghs G., Geys H., and Buyse M. Evaluation of surrogate end-points in randomized experiments with mixed discrete and continuous outcomes. Statist. Med. 20 (2001) 3023-3038
32. Prentice R.L. Surrogate endpoints in clinical trials: definitions and operational criteria. Statist. Med. 8 (1989) 431-440
33. Renard D., Geys H., Molenberghs G., Burzykowski T., and Buyse M. Validation of surrogate endpoints in multiple randomized clinical trials with discrete outcomes. Biometrical J. 44 (2002) 1-15
34. Royston P., Parmar M.K.B., and Qian W. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Statist. Med. 22 (2003) 2239-2256
35. Schatzkin A., and Gail M. The promise and peril of surrogate end points in cancer research. Natur. Rev. Cancer 2 (2002) 19-27
36. Schemper M., and Stare J. Explained variation in survival analysis. Statist. Med. 15 (1996) 1999-2012
37. Shannon C. A mathematical theory of communication. Bell Syst. Tech. J. 27 (1948) 379-423 623-656
38. Shih J.H., and Louis T.A. Inferences on association parameter in copula models for bivariate survival data. Biometrics 51 (1995) 1384-1399
39. Tibaldi F.S., Cortiñas Abrahantes J., Molenberghs G., Renard D., Burzykowski T., Buyse M., Parmar M., Stijnen T., and Wolfinger R. Simplified hierarchical linear models for the evaluation of surrogate endpoints. J. Statist. Comput. Simulation 73 (2003) 643-658
40. Verbeke G., and Molenberghs G. Linear Mixed Models for Longitudinal Data (2000), Springer, New York